Background: Drug-eluting bead transarterial chemoembolization (DEB-TACE) is a novel therapy for the treatment of hypervascuarized tumours. Through the intra-arterial delivery of microspheres, DEB-TACE allows for embolization as well as local release of chemotherapy in the treatment of hepatic malignancy, providing an alternative therapeutic option in unresectable tumours. Its role as an adjunct to surgical resection or radiofrequency ablation (RFA) is less clear. The purpose of this review is to summarize recent studies investigating DEB-TACE in order to better define safety, efficacy and outcomes associated with its use.
Introduction
Primary hepatic carcinoma remains a relatively uncommon disease in North America and Western Europe, representing 0.5-2.0% of all cancers. 1, 2 However, it represents a much larger proportion of malignancies (20-40%) in developing countries and is the fifth or sixth most common malignancy worldwide, accounting for approximately 5.6% of all cancers. 3, 4 Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver (70-85%); an estimated 500 000 to one million new cases occur annually and associated mortality amounts to approximately 600 000. 3, 5 Recent studies in the USA have shown that the incidence of HCC is increasing, probably in relation to chronic hepatitis C (HCV) infection. 6 Other causes of primary liver cancer are far less common and are led by cholangiocarcinoma (CCA), which occurs in 5000-6000 patients per year. 5 Despite recent increases in the incidence of HCC, metastatic liver disease still represents the majority of malignant hepatic neoplasms, with approximately 1.8 million cases per year. 7 Metastases to the liver can potentially derive from malignancy at any site in the body (including stomach, pancreas, biliary, renal, prostate, neuroendocrine, breast, melanoma, retroperitoneal sarcoma, ovarian, endometrial and cervix malignancies), as well as leukaemias and lymphomas. Colorectal cancer is the most common site of metastatic origin and the most relevant metastatic liver tumour to the surgeon because of the potential for longterm survival after complete resection of disease. 8 For this reason, other treatment modalities are being investigated for their roles in enhancing the results of surgical resection in liver disease to ensure the complete destruction of the tumour. 9 These include percutaneous ethanol injection (PEI), radiofrequency ablation (RFA), transarterial chemoembolization (TACE) and, more recently, drug-eluting bead transarterial chemoembolization (DEB-TACE).
Drug-eluting bead TACE is a drug delivery system that combines the local embolization of vasculature with the release of chemotherapy into adjacent tissue. 10, 11 It is intended for use in the treatment of hypervascular tumours such as HCC. Its administration is similar to that of conventional TACE and it represents a minimally invasive procedure performed by interventional radiologists. 10, 11 Beads are composed of biocompatible polymers such as polyvinyl alcohol (PVA) hydrogel that has been sulphonated to enable the binding of chemotherapy. 12 The beads occlude vasculature, causing embolization, and the chemotherapy is delivered locally. 13, 14 In this paper we investigate the results of recent clinical studies using DEB-TACE systems in the treatment of unresectable primary and metastatic liver carcinoma.
Materials and methods

Literature review
Details on DC Bead™ products were obtained from a review of all papers published in English-language peer review journals from 1995 to 2008. Unpublished studies and abstracts presented at national and international meetings were included. Trials were identified by conducting a comprehensive search of the MEDLINE, EMBASE, Science Citation Index, Current Contents and PubMed databases, using the medical subject headings 'colorectal liver metastasis' , 'hepatocellular carcinoma' , 'chemoembolization' , 'transarterial chemoembolization' and 'DC Bead' . A manual search of the abstracts was performed to identify papers for inclusion in this review. Only articles that included an evaluation of the DC Bead™ during this time period were included. The outline of articles reviewed is presented in Fig. 1 . The most commonly treated tumours included HCC, liver metastases, CCA and neuroendocrine cancer metastases. Eight clinical publications from 2006 to 2009 exploring the safety and efficacy of DEB-TACE (DC/LC Bead™; Biocompatibles UK Ltd, Farnham, UK) in the treatment of hepatic malignancy were reviewed (Table 1) . [15] [16] [17] [18] [19] [20] [21] [22] [23] Additionally, 19 abstracts were reviewed, 17 of which provided response rates, and all of which provided information on procedure-related complications ( Table 2) . Unpublished abstracts were presented between 2004 and 2008. Studies were evaluated according to type of tumour histology, stage of disease, resectability of malignancy, type of chemotherapy, DEB-TACE delivery technique, duration of follow-up, procedure-associated complications, and outcomes based on the Response Evaluation Criteria in Solid Tumours (RECIST), criteria defined by the European Association for the Study of the Liver (EASL) or other bases.
Results
Histology
Of the eight publications reviewed, five referred to primary hepatic carcinoma (four HCC, 15, 16, 19, 22 one CCA 21 ). The remaining three studies treated metastatic liver disease and included two on metastatic colorectal cancer, 17, 18 and one on metastatic neuroendocrine disease. 23 Of the abstracts, 14 provided response rates of HCC to treatment with DEB-TACE (Table 2 ). Three investigated the use of DEB-TACE in the treatment of metastatic colorectal carcinoma (MCRC) and provided response rates. A total of 19 provided data on safety and mortality associated with DEB-TACE in histologies including HCC, CCA, MCRC, metastatic neuroendocrine (MNE) disease, melanoma, and, in one study, metastases of various origins.
Patient selection
Patient selection among publications varied according to tumour histology. Inclusion and exclusion criteria were reviewed in an attempt to identify unifying themes. Some publications were more thorough in defining these criteria than others. 15, 23 Abstracts were reviewed in the same fashion, but were found to provide information even less consistently than publications.
A DC Bead™ loaded with doxorubicin (Adriblastin® and Adria-mycin® powder) has a target dose of 75 mg/2 ml and total doses should not exceed 150 mg/m 2 . 15 DC Bead™ loaded with epirubicin (Farmorubicin® 50 mg powder) has a target dose 75 mg/2 ml. DC Bead™ loaded with irinotecan (Campto® injection solution [100 mg/5 ml]) has a target dose of 100 mg/ 2 ml. 17, 18, 21 Patients undergo intra-arterial DEB administration using angiography. The catheter is placed as selectively as possible in order to isolate the blood supply to the malignancy and achieve localized chemotherapy. Selective hepatic embolization involves embolization of the right or left hepatic arteries separately as they branch from the proper hepatic artery. Superselective or highly selective embolization involves embolization of branches leading off from the hepatic arteries, preferably the lesion itself or its feeding branches. The size of DEB is chosen according to the particular study, usually with smaller particles (100-300 mm or 300-500 mm) being selected first, followed by larger particles (500-700 mm).
Multiple embolizations may be given to a quantity of three or four per 6-month period. 15, 22 Patients receiving embolization are monitored closely after each procedure in case hepatic failure develops or any other criteria become apparent that would exclude them from further therapy. Dose of chemotherapy used Potentially relevant publications identified and screened for retrieval n = 500
Publications retrieved for more detailed evaluation n = 8
RCTs excluded n = 482 List reasons n = Did not use DC Bead
Potentially appropriate publications to be included in the review n = 8
Publication included in review n = 8
RCTs with usable information, by outcome n = 8
Abstracts retrieved for more detailed evaluation n = 19
Abstracts appropriate for review n = 19 
Calculation of tumour response
Tumour response was calculated using either contrast-enhanced spiral computed tomography (CT) or magnetic resonance imaging (MRI) with quantification of tumour response according to either RECIST or EASL criteria. 16 Treatment response using RECIST response criteria was categorized as complete response (CR) or partial response (PR). Complete response is defined by the disappearance of measurable disease, or the absence of arterial phase contrast enhancement as measured by CT, persisting for Ն4 weeks without the appearance of new measurable lesions. Partial response is defined as a Ն30% reduction in the sum of the products of the greatest diameter (length) and the greatest perpendicular diameter (width) of all measurable lesions compared with baseline, and no appearance of new measurable lesions. Stable disease (SD) represents cases in which neither PR nor progressive disease (PD) criteria are met, taking as reference the smallest sum of the greatest diameter recorded since the commencement of treatment. Progressive disease (PD) is defined by the occurrence of one of the following conditions: (i) the sum of the cross products of all measurable lesions, including new lesions, increases by >50% compared with the nadir, or (ii) new measurable lesions occur in any part of the body outside the liver. 24 Treatment response assessment using EASL criteria represented a measure of local tumour response based on tumour progression with respect to change in necrosis. The greatest diameter of viable tumour against greatest total tumour diameter is measured and initial measurements are compared with those after each chemoembolization treatment. 25 New tumour development in a previously treated area is not considered as progression.
Stage and resectability
Tumours were categorized as being unresectable in eight of eight publications (Table 1) . One additional publication not included investigated outcomes in HCC after initial RFA failure followed by DEB-TACE. 20 Patients selected for studies treating HCC were classified as Child-Pugh class A only in three of four studies. 16, 19, 22 The remaining study treated both Child-Pugh classes A and B patients. 15 All publications required patients to have an HCC diagnosis confirmed by either clinical criteria (EASL) or biopsy. Patients did not have HCC that was suitable for resection, liver transplantation (Table 3) . Patient exclusion criteria for the treatment of HCC in all publications included bilirubin levels >3 mg/dl, advanced tumoral disease including vascular invasion and extrahepatic spread, contraindications to doxorubicin administration (white blood cell count >3000 cells/mm 3 , neutrophils <1500 cells/mm 3 , cardiac ejection fraction <50%), any contraindication to hepatic embolization procedures (portosystemic shunts, hepatofugal blood flow, impaired coagulation [platelet count <50 000/mm 3 , prothrombin activity <50%]), renal insufficiency or failure (serum creatinine >2 mg/dl), and severe atheromatosis.
Inclusion criteria for the treatment of MCRC included histologically confirmed colorectal carcinoma with metastatic disease confirmed by CT, Karnofsky performance status Ն60% or World Health Organization (WHO) criteria performance status of 0-2. Patients were required to have undergone previous chemotherapy discontinued Ն4 weeks prior to beginning the study and to have no signs of infection or ascites (Table 3 ). Other criteria varied between studies and included normal metabolic and laboratory testing, life expectancy of Ն3 months and age <85 years.
Exclusion for MCRC included any history of inflammatory bowel disease or previous extensive bowel resection, signs of cardiac disease, or renal, bone marrow, pulmonary or central nervous system metastases. Uncontrollable infections, as well as other types of cancer (except treated in situ cervical, basal cell carcinoma or squamous cell carcinoma) were excluding factors. One study excluded patients with prior treatment with topoisomerase inhibitors.
Patients with CCA included in a single study by Aliberti et al. were required to have a Karnofsky performance score >60%, tumour substitution <60% and normal liver function levels up to twice the upper limit of normal. 21 Other than failure to meet the aforementioned inclusion criteria, no exclusion criteria were specified (Table 3) .
Inclusion criteria for a single study evaluating treatment of MNE disease by de Baere et al. required patients to be aged 18-75 years, and to have histologically proven disease with two or fewer mitoses per high-powered field, and proven progressive disease on two subsequent imaging studies according to RECIST criteria, including an increase in the size of known liver metastases (Table 3 ). 23 Additional criteria included serum bilirubin less than twice the upper limit of normal, serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels less than three times the upper limit of normal, serum creatinine levels <120 mol/l, prothrombin time lower than 1.5 IU and a platelet count of >10 6 /mm 3 .
Exclusion criteria in this study excluded candidates with any resectable disease, predominant extrahepatic disease, biliary tract dilation, bilioenteric anastomosis or biliary stent crossing the ampulla of Vater, and previous treatment with TACE.
Delivery technique
Doxorubicin was the chemotherapeutic agent used in the treatment of all HCC publications and most abstracts (Tables 1 and 2) . Doxorubicin doses commenced with delivery of 25 mg/m 2 and ranged up to a maximum dose of 150 mg/m 2 . Irinotecan was used in treating those with MCRC. Irinotecan was administered at doses of 100 mg per TACE procedure. Drug-eluting bead TACE was administered using angiography to determine the catheter placement and to embolize as selectively as possible. Bead size varied from 100-300 mm to 500-700 mm across studies, depending on the size of the vessel embolized and patency following initial embolization.
Response rates
Using EASL criteria, publications following the treatment of HCC reported overall response (OR) rates of 65% (66/101; CR 5%, PR 60%) at 1 month, 71% (65/91; CR 9%, CR 63%) at 4 months, 75% (61/81; CR 14%, PR 62%) at 6-7 months and 88% (7/8; CR 25%, PR 63%) at 10 months (Table 4 ). Stable disease rates were reported as 27% (27/101) at 1 month, 12% (11/91) at 4 months, 12% (10/81) at 6-7 months and 13% (1/8) at 10 months. Progressive disease rates were reported at 7% (7/101) at 1 month, 16% (15/91) at 4 months, 9% (7/81) at 6-7 months and 0% (0/8) at 10 months (Table 4 ). An investigation by Lencioni et al. involving combination therapy of RFA with DEB-TACE using EASL criteria reported an OR of 75% (CR 50%, PR 25%) in 20 patients with HCC at 12 months, as well as SD and PD rates of 0% and 25%, respectively. 20 Using RECIST criteria, publications treating HCC reported OR rates of 50% (15/30) at 1 month (CR 0%, PR 50%, SD 27%, PD 23%). Overall response at 4 months was 36% (10/28; CR 0%, PR 36%, SD 18%, PD 46%). Overall response at 6 months was 42% (24/57; CR 14%, PR 28%, SD 38%, PD 20%). A single study reporting response rates at 6 months did not account for five of 30 (17%) patients involved in the study; therefore those patients were not included in response rate calculations.
Among those investigations of HCC using RECIST criteria, two abstracts reported OR rates of 9% and 19% at 1 month (Kalva et al. 26 ; Reyes et al. 27 ; Tables 2 and 4 ). The abstract with 19% OR (Reyes et al.) also reported an SD rate of 71% and a PD rate of 10% in 23 patients. Two abstracts reported response rates at 2 and 3 months with ORs of 29% (6/21) and 50%, respectively (Kalva et al.; Reyes et al.) . The abstract reporting 3-month responses had an SD rate of 43% and a PD rate of 7%. One publication 19 and one abstract reporting response rates at 6 months had OR rates of 44% and 52% (CR 0%, PR 52%), respectively. Malagari reported an OR of 62% in 62 patients at the 2-year follow-up, 29% of whom exhibited SD. 15 Aliberti et al. studied response rates in CCA at 3 months using RECIST criteria and found an OR rate of 100% (11/11; CR 9%, PR 82%, SD 0%, PD 0%) ( Table 5 ). 21 A single patient in this study was unaccounted for and therefore excluded from statistics. Fiorentini et al. evaluated MCRC in a single publication using RECIST Table 3 Response rates according to criteria and length of follow-up in different malignancies 23 Overall response rates were 50% (10/20) at 1 month (CR 0%, PR 50%, SD 45%, PD 5%) and 80% (16/20) at 3 months (CR 0%, PR 80%, SD 15%, PD 5%). 23 
Safety
The various publications reported complications according to two methods: by procedure and by patient ( Table 1 ). The most common procedure-associated complications included fever (85% of patients, 46% of procedures), nausea and vomiting (93% of patients, 52% of procedures), abdominal pain (80% of patients, 44% of procedures) and liver abscess (2% of patients, 1% of procedures). Rather than describing individual symptoms, two studies reported post-embolic syndrome (PES), consisting of fever, abdominal pain and nausea or vomiting, as occurring in 82% (75/91) of patients. Six of nine studies reported length of hospital stay, which averaged 2.3 days per procedure. Mortality was reported to occur in 11 in 533 (2%) procedures, or in 11 in 253 (5%) patients. Causes of mortality included myocardial infarction (n = 3), progressive liver disease (n = 5), pulmonary embolism (n = 1), postoperative sepsis (n = 1) and liver failure (n = 1). Additional complications included mild asthenia (n = 8), alopecia (n = 7), acute cholecystitis (n = 2), hepatic infarction (n = 2), pulmonary effusion (n = 1), gastric ulcer haemorrhage (n = 1), variceal bleed (n = 1), spontaneous bacterial peritonitis (n = 1), rash (n = 1) and pancreatitis (n = 1). A transient increase in liver function enzymes was reported in most studies. Abstracts were less consistent in reporting complications. Fever was reported as a common side-effect in 77% (30/39) of studies and as a frequent complication in five other studies. Nausea and vomiting was reported as a common side-effect in 70% (21/30) of studies and as a frequent complication in four other studies. Right upper quadrant pain was reported in 53% (40/75) of patients and was frequent in four additional studies. Post-embolic syndrome was reported in place of the aforementioned symptoms in 66% (80/122) of studies and occurred in some patients in two additional studies, although numbers were not quantified. One study reported hospital stay as averaging 1.8 days. Mortality was reported as occurring in 36 of 698 patients (5%). Causes included progressive disease (n = 14), hepatic failure (n = 3), postoperative sepsis (n = 2, cardiovascular disease (n = 2), myocardial infarction (n = 1), pulmonary embolism (n = 1), head trauma (n = 1), death following gastric ulcer repair (n = 1) and were not specified (n = 11). Additional complications included hepatic failure (n = 7), pancreatitis (n = 5), cholecystitis (n = 3), gastritis (n = 2), enteritis (n = 2, of which one was a hemorrhagic duodenitis), acute renal failure (n = 1), hepatic rupture (n = 1), hepatic infarction (n = 1) and fistula formation between the duodenum and tumour (n = 1). Other complications included skin rash, decreased appetite, decreased libido, fatigue, alopecia, asthenia, leucocytopenia, anaemia, thrombocytopenia, neutropenia, hypoalbuminaemia and transiently increased liver function enzymes.
Discussion
We do not yet have a standardized method for reporting data on the utilization of various therapies in hepatic disease, including Yttrium-90, transarterial embolization, TACE and DEB-TACE. This makes it difficult to compare current results because of the variability across studies, such as in the number of cycles of DEB administered, total doses of chemotherapy given to patients, differences in inclusion and exclusion criteria, and differences in the criteria used to report responses. The method of data reporting in publications and abstracts did not allow for comparisons of individual patient response by number of treatments received. However, despite these inconsistencies, considerable response to therapy was evident in studies that followed patients within the first year of treatment. Certain trends can be seen clearly, such as an increase in overall response in patients who received additional cycles of DEB-TACE and higher levels of chemotherapy. Patients who did not respond adequately to initial therapy and who did not have significant toxicity were candidates for additional treatments until either adequate response was achieved or they received the maximal dose of chemotherapy. It will be helpful to correlate these factors with response criteria in future studies in order to determine whether overall response is significantly dependent on multiple treatments.
The difference in response reported by EASL criteria vs. that reported by RECIST criteria was also notable. Among publications reporting both criteria (i.e. Poon et al. 16 ), using EASL criteria gave larger tumour response rates than did RECIST criteria. The latter criteria determine measurements based on the extent of measurable disease and the presence of arterial phase on CT, but do not take the extent of necrosis into consideration. However, EASL-based criteria contrast with RECIST criteria because they include measurement of tumour necrosis as well as viable tumour in order to determine the extent of response. Although results based on different criteria varied, longterm response and survival rates should not vary because DEB-TACE administration was similar independent of evaluation criteria. Those studies reporting response rates by unknown criteria could not be accurately compared with EASL-or RECIST-based studies, but still provided valuable information concerning overall tumour response. Data from abstracts, although helpful in reporting initial response rates and procedure-related safety, should not be compared with published data until the studies to which the abstracts pertain have been finalized. Information was not consistently reported among abstracts, with the result that some values obtained, specifically complication rates, are less valuable because of the lack of patient numbers.
Short-term follow-up provided valuable information concerning response rates. Although short-term evaluation indicates that the procedure effectively embolizes and causes tumour necrosis, continued follow-up is essential in order to determine the longterm significance of DEB-TACE and its role as an alternative therapy or palliative measure in treating patients with hepatic malignancy. Some abstracts described ongoing studies investigating the use of DEB-TACE over an extended follow-up period, such as a 2-year study by Malagari et al., which followed 62 patients. Another abstract that might provide significant information refers to a study by Hong et al., which followed 190 patients treated with DEB-TACE for Յ1 year. Low rates of disease progression and procedure-related mortality associated with current publications are encouraging, but time will be a major factor in determining overall benefit.
Drug-eluting bead TACE appears to be a relatively safe procedure, with few longterm serious complications associated with its administration. Although symptoms of PES, such as fever, nausea or vomiting and abdominal pain appear to occur in most patients, these symptoms are associated with short hospital stays averaging 2.3 days among publications, which is significantly lower than for conventional TACE procedures. The most frequent major complication associated with this procedure was liver abscess, which occurred in approximately 0.75-1.58% of publications and approximately 0.29% of abstracts. Other complications were infrequent, although some were quite severe. Overall mortality is potentially lower than the reported values (2.06-4.74% in publications and 5.16% in abstracts) because reported mortality rates included both procedure-related causes of death, such as sepsis and hepatic failure, and death secondary to progressive disease, cardiovascular disease, pulmonary embolism and other causes. Patients selected for these studies are predisposed to co-morbidities as a result of their diminished hepatic function and potentially other age-or lifestyle-related conditions, which should be taken into consideration.
Use of DEB-TACE in current publications seems to be restricted to patients with unresectable liver disease and reasonable hepatic function (Child-Pugh classes A and B). Future publications are considering patients with more severe disease; for example, two abstracts by Kalva et al. and Malagari et al. report the inclusion of Child-Pugh class C patients. A study by Lencioni et al. was the only publication to address the use of DEB-TACE as combination therapy with RFA. 20 At the 1-year follow-up, an OR of 75% using EASL criteria was documented. Although no comparisons can be drawn because no similar studies have been reported, several abstracts were of similar design. Combination therapy may prove to be effective as an alternative treatment in unresectable liver disease. Other interesting uses of DEB-TACE mentioned in abstracts include as emergent therapy for the purpose of embolizing ruptured tumours in patients with HCC.
Conclusions
The current results show DEB-TACE to produce beneficial tumour response and to have exceptionally low complication rates. The technique has the potential to become an effective alternative therapy or palliative measure in the treatment of hepatic malignancy, but both delivery and data collection must be standardized in order to clarify efficacy. It is a safe alternative in the treatment of unresectable hepatic malignancy, but is unproven as an adjunctive treatment to other standard therapies such as resection and RFA. Further investigation is essential to better define its role as an adjunct in treating hepatic malignancy.
